ICU

$2.48

Market ClosedAs of Mar 17, 8:00 PM UTC

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.48
Potential Upside
5%
Whystock Fair Value$2.60
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytophereti...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-290.37%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.44

Recent News

GuruFocus.com
Nov 14, 2025

SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Highlights: Revenue Surge and ...

SeaStar Medical Holding Corp (ICU) reports a 45% revenue increase and strategic growth in pediatric hospitals, while addressing trial enrollment challenges and revenue variability.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Nov 13, 2025

SeaStar Medical (ICU) Q3 2025 Earnings Transcript

Eric Schlorff: Thank you, Jackie, and thank you all for joining us today. Since the beginning of the third quarter, we advanced our business on several fronts that we believe position us well for our future growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Aug 14, 2025

SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...

SeaStar Medical Holding Corp (ICU) reports a 370% revenue increase and significant clinical trial progress, despite challenges in customer adoption and operating expenses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Jun 25, 2025

Top Midday Gainers

Plus Therapeutics (PSTV) said Wednesday that the US Food and Drug Administration has cleared its inv

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
May 15, 2025

SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Highlights: Revenue Surge and ...

SeaStar Medical Holding Corp (ICU) reports a fourfold revenue increase, new FDA designations, and significant market opportunities in its latest earnings call.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.